Shire and Shionogi report positive Intuniv data from adult ADHD trial

Shire has announced the findings of a new clinical trial that demonstrate the strong performance Intuniv can offer to adult patients with attention deficit hyperactivity disorder (ADHD).

Results from the new phase III study showed that the therapy delivered superiority over placebo in ADHD symptom improvement among patients aged 18 and over, meeting the primary endpoint of the trial.

This study was conducted in Japan with cooperation from Shionogi, with the aim of securing approval for Intuniv for the treatment of ADHD in adult patients in this territory. Japan is the world's third-largest ADHD market, growing at more than 20 percent annually.

Additionally, this was the first clinical trial evaluating Intuniv in adult patients with ADHD, with the drug having already demonstrated considerable benefit in the treatment of children and adults.

Dr Brigitte Robertson, vice-president and head of global clinical development for neuropsychiatry at Shire, said: "The positive topline results of this phase III study provide us with important data and insights regarding the clinical profile of Intuniv in adult patients with ADHD."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.